

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited **國藥科技股份有限公司**

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 8156)

RE-DESIGNATION OF EXECUTIVE DIRECTOR AND CHAIRPERSON OF THE BOARD AND CHANGE IN COMPOSITION OF NOMINATION COMMITTEE

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinopharm Tech Holdings Limited (the “**Company**”) announces that Madam CHEUNG Kwai Lan (“**Madam CHEUNG**”) has been re-designated from executive Director to non-executive Director of the Company, from chairperson of the Board to honorary chairperson of the Company, and has resigned as chairperson and member of nomination committee of the Company with effect from 7 January 2021.

The Board further announces that Mr. CHAN Ting (“**Mr. CHAN**”) has been re-designated from deputy chairperson to the chairperson of the Board and has been appointed as the chairperson and member of the nomination committee of the Company with effect from 7 January 2021.

Madam CHEUNG Kwai Lan

Madam CHEUNG, aged 82, was one of the founders of the Company and its subsidiaries (the “**Group**”). She has served the Group for more than 20 years and is the director of various subsidiaries of the Group. She is the director of Best Frontier Investments Limited, the substantial shareholder of the Company. Madam CHEUNG was responsible for corporate development and strategic planning of the Group. Madam CHEUNG graduated from Shanxi Taiyuan Medical School in 1960 and was a researcher at Shanxi Province Taiyuan (Atomic Energy) Research Institute (山西省太原（原子能）研究所), which was one of the institutions of the Chinese Academy of Science. She also participated in the research and development of the radioactive material Cobalt 60 for imaging and cancer treatment. Madam CHEUNG has been engaged in commercial development in Hong Kong for almost 40 years.

Madam CHEUNG has keen interest in social welfare and charity works. She is currently the

chairperson of Zhang Xueliang Foundation, permanent honorary chairperson of the World of Chinese & Overseas Chinese Peace Promote Association, director of the China Legal Aid Foundation under the Ministry of Justice, vice chairperson of the “Chinese Charitable Work Development Association” (中國公益事業發展聯合會), and honorary director of “Chinese Si Hai Tong Xin Association in Taiwan” (台灣中華四海同心會). Madam CHEUNG attended the 2nd conference of the 11th National Committee of the Chinese People’s Political Consultative Conference as an overseas compatriot by special invitation. She has also been awarded as “China Philanthropy Outstanding Contribution Individual”, “Most Influential Entrepreneur in China”, “International Philanthropic Celebrity”, “International Philanthropic Stars” and “Progeny of the PRC for the 60 Years Development of New China”.

Madam CHEUNG is the mother of Ms. CHAN Siu Sarah and Mr. CHAN Ting, and is the spouse of Mr. CHAN Tung Mei, being the Group General Counsel, executive Director and non-executive Director of the Company respectively.

Madam CHEUNG has not entered into any service contract for her directorship as the non-executive Director with the Company. She will be entitled to receive a director’s fee of HK\$240,000 per annum which was determined by the Board based on recommendation of the remuneration committee of the Company and with reference to the prevailing market conditions, her relevant roles, duties and responsibilities in the Company. She is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the articles of association of the Company.

As at the date of this announcement, Madam CHEUNG has the following interest in the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “SFO”):

<u>Capacity</u>	<u>Nature of interest</u>	<u>Number of shares</u>
held by Best Frontier Investments Limited	ordinary shares	632,920,856
beneficially owned	ordinary shares	4,656,000
beneficially owned	share options	4,000,000
held by spouse	ordinary shares	3,020,000
held by spouse	share options	3,600,000

Save as disclosed above, Madam CHEUNG (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the SFO; (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the Rules Governing the Listing of Securities on GEM (“GEM”) of The Stock Exchange of Hong Kong Limited (the “GEM Listing Rules”)) of the Company nor does she hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to Madam CHEUNG’s re-designation is needed to be brought to the attention of the shareholders of the Company.

Mr. CHAN Ting

Mr. CHAN, aged 51, is the executive Director, chief executive officer, compliance officer and authorised representative of the Company. He is also a member of the remuneration committee of the Company. He has served the Group for more than 19 years and is the director of various subsidiaries of the Group. He is the director of Best Frontier Investments Limited, the substantial shareholder of the Company. He is responsible for marketing, business development, strategic planning and operations of the Group. He was awarded a bachelor's degree in Economics from Macquarie University in Australia in 1993. He is the Vice President of the Zhang Xueliang Foundation. Mr. CHAN has over 25 years of working experience in establishing and managing companies in the PRC.

Mr. CHAN is the son of Madam CHEUNG and Mr. CHAN Tung Mei, being the honorary chairperson and non-executive Director, and non-executive Director of the Company respectively, and the brother of Ms. CHAN Siu Sarah, the Group General Counsel. He joined the Group in July 2001.

Mr. CHAN has entered into a renewable service agreement for his directorship as the executive Director with the Company for a term of three years, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the articles of association of the Company. He will be entitled to receive an annual salary and other allowance of HK\$3,000,000 and an annual director's fee of HK\$240,000 which were determined by the Board based on recommendation of the remuneration committee of the Company and with reference to his relevant roles, duties and responsibilities in the Company, the prevailing market conditions and the Company's performance.

As at the date of this announcement, Mr. CHAN has 4,000,000 share options of the Company. Save as disclosed above, Mr. CHAN (i) does not hold any interest in the shares or underlying shares of the Company within the meaning of Part XV of the SFO; (ii) does not hold any directorship in any Hong Kong or overseas listed public companies in the last three years; and (iii) does not have any relationship with any Director, senior management or substantial or controlling shareholder(s) (as defined in the GEM Listing Rules) of the Company nor does he hold any position in the Company or any of its subsidiaries.

Save as disclosed above, neither any further information is required to be disclosed pursuant to the requirements under Rule 17.50(2)(h) to (v) of the GEM Listing Rules nor any other matter relating to Mr. CHAN's re-designation is needed to be brought to the attention of the shareholders of the Company.

The Board would like to take this opportunity to express its gratitude and appreciation to Madam CHEUNG's past valuable contribution to the Company during her term of office as the chairperson of the Board, executive Director and chairperson of the nomination committee of the Company and to express its warmest welcome to Mr. CHAN for his new roles in the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAN Ting
Chairperson

Hong Kong, 7 January 2021

As at the date of this announcement, the Board comprises Mr. CHAN Ting as executive Director, Madam CHEUNG Kwai Lan, Mr. CHAN Tung Mei and Dr. CHENG Yanjie as non-executive Directors and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. CHAU Wai Wah Fred as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkgem.com for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.